More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$87395809
EPS
-3.33
P/E ratio
--
Price to sales
24.9
Dividend yield
--
Beta
1.62841
Previous close
$1.74
Today's open
$1.73
Day's range
$1.61 - $1.77
52 week range
$1.09 - $4.24
show more
CEO
Peter Beetham
Employees
183
Headquarters
San Diego, CA
Exchange
NASDAQ Capital Market
Shares outstanding
54283111
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council
Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European growers
GlobeNewsWire • Dec 11, 2025

Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript
Cibus, Inc. ( CBUS ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Carlo Broos - Chief Financial Officer Peter Beetham - Co-Founder, Interim CEO, President, COO & Director Gregory Gocal - Co-Founder, Chief Scientific Officer & Executive VP Conference Call Participants Kevin Estok - Jefferies LLC, Research Division Matthew Venezia - Alliance Global Partners, Research Division Sameer Joshi - H.C. Wainwright & Co, LLC, Research Division Austin Moeller - Canaccord Genuity Corp., Research Division Alex Hantman - Sidoti & Company, LLC Presentation Operator Good afternoon, everyone, and welcome to the Cibus Third Quarter 2025 Results Conference Call.
Seeking Alpha • Nov 14, 2025

Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025
With the addition of Centro Internacional de Agricultura Tropical (CIAT) in the quarter, Cibus now has 5 LATAM Rice customers as momentum continues toward achieving 2027 targeted initial LATAM Rice revenue On track to deliver HT traits to Latin American customer in Q4 2025 with field trials expected to commence by year end Engaged strategic growth advisory firm AgVayā to introduce Indian Rice growers to new solutions to scale crop productivity through advanced gene editing Su ccessfully completed pre-commercial pilot runs for certain biofragrance products; commercial expansion targeted for 2026 Positive field trial results for HT2 in Canola in North America ; HT2 and Sclerotinia resistance traits available for seed licensing partners for funded continued development opportunity Initiated additional actions to support streamlined business focus prioritizing nearest-term and partner-funded commercial opportunities while the Company targets a reduced annual net cash usage of $30 million by 2026, and completed consolidation of Oberlin facility activities Appointed Kimberly A. Box and Craig Wichner to Cibus' Board of Directors, which strategically strengthens Cibus' commercial expansion support SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended September 30, 2025, and provided a year-to-date business update for 2025.
GlobeNewsWire • Nov 13, 2025

Cibus (CBUS) Reports Q3 Loss, Misses Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to earnings of $0.06 per share a year ago.
Zacks Investment Research • Nov 13, 2025

Cibus Announces the Election of Craig Wichner to Board of Directors
Appointment underscores company's commitment to long-term shareholder value creation and sustained business growth Appointment underscores company's commitment to long-term shareholder value creation and sustained business growth
GlobeNewsWire • Nov 11, 2025

Cibus to Report Third Quarter 2025 Financial Results on November 13, 2025 After the Market Close and Host Conference Call
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report third quarter 2025 financial results on Thursday, November 13, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m.
GlobeNewsWire • Oct 30, 2025

Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing
Collaboration aims to accelerate the adoption of advanced gene editing technologies in and deliver high-performance traits that support more sustainable and productive rice production in India Collaboration aims to accelerate the adoption of advanced gene editing technologies in and deliver high-performance traits that support more sustainable and productive rice production in India
GlobeNewsWire • Oct 16, 2025

Soybean Short Squeeze: Cooking Oil Stocks Pop After Trump Targets China
Soybean-related stocks exploded on Wednesday following President Donald Trump's latest comments in the ongoing trade war with China.
Benzinga • Oct 15, 2025

Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola
Field testing confirms efficacy of HT2 trait in Canola under real-world conditions HT2 trait will be offered to potential seed licensing partners for introduction into commercial Canola seed products SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company developing and licensing advanced gene edited plant traits that enable improved productivity, higher yields, lower input costs, and more sustainable farming, today announced the completion of field testing for its second-generation herbicide tolerance (HT2) edited Canola with positive results. “Our second-generation herbicide tolerance edited canola previously performed well in greenhouse trials and has now shown positive results in our 2025 Canola field trials,” said Jim Radtke, PhD, Senior VP of Product Development at Cibus.
GlobeNewsWire • Oct 2, 2025

Cibus Announces the Election of Kimberly A. Box to Board of Directors
Appointment strengthens governance and commercialization strategy expertise as Cibus continues preparations for launch of its advanced trait technologies delivering crop productivity and sustainability solutions to farmers Appointment strengthens governance and commercialization strategy expertise as Cibus continues preparations for launch of its advanced trait technologies delivering crop productivity and sustainability solutions to farmers
GlobeNewsWire • Sep 25, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Cibus Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.